Why VYXEOS for sAML treatment?
A variety of factors are considered when determining whether or not VYXEOS (vix-e-ose) is the right treatment. These factors may include your age, your overall health, and whether you have a confirmed diagnosis of secondary acute myeloid leukemia (sAML), specifically therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Only a healthcare provider can decide if VYXEOS is the best course of treatment.
Individual results may vary.
Please see Important Safety Information, including Boxed Warning for VYXEOS at the bottom of this page and the full Prescribing Information.
How VYXEOS may help
VYXEOS provides a chance to live longer and allows you to spend less time connected to an intravenous (IV) infusion line during treatment compared to the standard chemotherapya treatment
In a clinical trial including older adults with t-AML or AML-MRC in which 153 people received VYXEOS and 156 people received the standard chemotherapya treatment for AML:
In this clinical trial, people with sAML treated with VYXEOS lived longer than those treated with standard chemotherapy.a
Median survival timeb
Estimated survivalc at 1 year after the start of treatment
In this clinical trial, more people with sAML treated with VYXEOS achieved a complete responsed than those treated with standard chemotherapya
Secondary AML patients who achieved a complete responsed
In this clinical trial, more people with sAML treated with VYXEOS received transplant after treatment
Secondary AML patients who received a hematopoietic stem cell transplant (HSCT)
- Standard chemotherapy was cytarabine 100 mg/m2 and daunorubicin 60 mg/m2.
- Median survival time refers to the time when half of the people in the trial were alive.
- Estimated survival was based on Kaplan-Meier-estimated percentages of the people in the trial who were still alive 1 year after the start of treatment.
- Complete response, also known as complete remission (CR): when leukemia cells make up less than 5% of cells in your bone marrow and your blood cell counts are back to normal.
VYXEOS may cause serious side effects, including:
Fever, signs of infection, or bruising or bleeding which can result in serious infection and/or bleeding and possibly lead to death. You should tell your doctor about new onset fever or symptoms of infection or if you notice signs of bruising or bleeding.
Signs of heart failure such as shortness of breath or trouble breathing; swelling or fluid retention, especially in the feet, ankles, or legs; or unusual tiredness.
Skin damage which can occur if VYXEOS leaks out of the vein. Tell your doctor right away if you experience symptoms of burning, stinging, or blisters and skin sores at the injection site.
Signs of hypersensitivity reactions, including anaphylaxis such as difficulty breathing, severe itching, skin rash and hives, or swelling of the face, lips, mouth, or tongue. Seek immediate medical attention if you develop any of these signs or symptoms.
These are not all of the possible side effects of VYXEOS. Be sure to speak to your healthcare team about any side effects you have.
Please see full Prescribing Information, including BOXED Warning, and discuss with your doctor.